

# Kyowa Hakko Kirin Co., Ltd.

## Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2018 First Quarter

(January 1, 2018 - March 31, 2018)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on May 8, 2018 for the first three months of Fiscal 2018, from January 1, 2018 to March 31, 2018.
- This document is an English translation of parts of the Japanese-language original. The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Figures presented in these materials have been rounded to the nearest tenth.
- Figures inside parenthesis presented in these materials indicate negative values.

Index	Page
I. Consolidated Financial Results (IFRS)	
1. Trends in consolidated profit	1
2. Revenue by geographic region	1
3. Other trends	2
II. Consolidated Statement of Cash Flows (IFRS)	2
III. Core Operating Profit or Loss by Segment (IFRS)	3
IV. Revenue from Main Products of Pharmaceuticals Segment (IFRS)	4
V. R&D Pipeline	5

The average exchange rate for each period was as follows:

*Unit: Yen*

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Mar	Jan - Dec	Jan - Mar	Jan - Dec
USD	115	112	110	110
EUR	122	126	134	130
GBP	143	144	152	150

<p>Contact            Kyowa Hakko Kirin Co., Ltd.            Corporate Communications Department            Tel +81 3 5205 7206</p>
---

## I. Consolidated Financial Results (IFRS)

### 1. Trends in consolidated profit

Unit: Billions of yen, rounded to the nearest tenth

	FY 2017 results		FY 2018 results		FY 2018 forecasts	
	Jan - Mar	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	%
Revenue	91.3	353.4	84.7	(6.6)	335.0	95%
Cost of sales	(35.1)	(129.1)	(31.0)	4.1	(114.0)	88%
Gross profit	56.2	224.3	53.8	(2.5)	221.0	99%
Selling, general and administrative expenses	(26.2)	(113.0)	(28.0)	(1.8)	(117.0)	104%
Research and development expenses	(12.0)	(49.2)	(10.9)	1.1	(49.5)	101%
Share of profit (loss) of investments accounted for using equity method	(1.3)	(4.5)	1.4	2.7	(3.5)	78%
Core operating profit	16.8	57.7	16.2	(0.5)	51.0	88%
Other income	0.8	6.6	14.5	13.7	-	-
Other expenses	(0.2)	(8.4)	(0.2)	0.0	-	-
Finance income (costs)	(0.0)	(0.1)	(0.3)	(0.3)	-	-
Profit before tax	17.4	55.8	30.3	12.9	61.0	109%
Income tax expense	(5.4)	(13.0)	(8.3)	(2.9)	-	-
Profit	12.0	42.9	22.0	10.0	44.0	103%

EPS (¥/share)	21.96	78.38	40.20	18.24	80.39	-
Annual dividend (¥/share)	-	27.00			30.00	-
Dividend payout ratio (%)	-	34.4			37.3	-
ROE (%)	-	7.2	-	-	-	-

\* "FY 2018 forecasts" have not been revised from the consolidated results forecasts released on February 8, 2018.

### 2. Revenue by geographic region

Unit: Billions of yen, rounded to the nearest tenth

	FY 2017 results			FY 2018 results		FY 2018 forecasts	
	Jan - Mar	Jan - Dec	Percentage of consolidated revenue	Jan - Mar	Percentage of consolidated revenue	Jan - Dec	Percentage of consolidated revenue
Japan	60.5	240.9	68.2%	55.2	65.2%	221.2	66.0%
International	30.8	112.5	31.8%	29.5	34.8%	113.8	34.0%
Americas	7.5	24.7	7.0%	6.7	7.9%	29.7	8.9%
Europe	15.8	56.0	15.8%	15.1	17.8%	55.2	16.5%
Asia	7.2	30.2	8.6%	7.5	8.9%	28.0	8.3%
Others	0.3	1.6	0.5%	0.3	0.3%	0.9	0.3%
Total consolidated revenue	91.3	353.4	100%	84.7	100%	335.0	100%

\* Revenue is classified by region or country based on location of customer.

### 3. Other trends

#### (1) Research and development expenses

*Unit: Billions of yen, rounded to the nearest tenth*

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Mar	Jan - Dec	Jan - Mar	Jan - Dec
Research and development (R&D) expenses	12.0	49.2	10.9	49.5
<i>R&amp;D expenses to revenue ratio</i>	13.1%	13.9%	12.9%	14.8%
Pharmaceuticals	11.3	46.1	10.2	46.5
<i>R&amp;D expenses to revenue ratio</i>	15.6%	16.7%	15.3%	17.7%
Bio-Chemicals	0.8	3.1	0.8	3.0

#### (2) Capital expenditures (property, plant and equipment)

*Unit: Billions of yen, rounded to the nearest tenth*

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Mar	Jan - Dec	Jan - Mar	Jan - Dec
Capital expenditures	3.3	14.3	2.4	12.5
Pharmaceuticals	2.2	6.6	0.8	5.3
Bio-Chemicals	1.1	7.7	1.6	7.2

#### (3) Depreciation and amortization (property, plant and equipment and intangible assets)

*Unit: Billions of yen, rounded to the nearest tenth*

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Mar	Jan - Dec	Jan - Mar	Jan - Dec
Depreciation and amortization	5.5	22.0	5.1	24.6
<i>Amortization of intangible assets</i>	2.1	7.8	2.1	9.1
Pharmaceuticals	3.9	15.3	3.8	17.3
<i>Amortization of intangible assets</i>	2.1	7.7	2.1	9.1
Bio-Chemicals	1.6	6.7	1.4	7.3

## II. Consolidated Statement of Cash Flows (IFRS)

*Unit: Billions of yen, rounded to the nearest tenth*

	FY 2017 results		FY 2018 results	
	Jan - Mar	Jan - Dec	Jan - Mar	Change amount
<b>Cash flows from operating activities</b>	18.9	64.9	19.5	0.6
<b>Cash flows from investing activities</b>	(10.1)	(45.3)	(14.5)	(4.4)
<b>Cash flows from financing activities</b>	(6.7)	(18.3)	(8.3)	(1.6)
Effect of exchange rate changes on cash and cash equivalents	1.2	1.3	(0.1)	(1.3)
Net increase (decrease) in cash and cash equivalents	3.3	2.7	(3.5)	(6.7)
Transfer to assets held for sale	-	(1.1)	1.1	1.1
Cash and cash equivalents at beginning of period	13.1	13.1	14.7	1.6
<b>Cash and cash equivalents at end of period*</b>	16.4	14.7	12.3	(4.1)

\* Cash reserves at end of period

Cash and cash equivalents at end of period	16.4	14.7	12.3	-
Loans receivable from parent in excess of three months	120.0	143.2	168.0	-
Time deposits whose maturity periods exceed three months	0.0	0.0	0.0	-
Cash reserves at end of period	136.4	157.9	180.3	-

**III. Core Operating Profit or Loss by Segment (IFRS)**
**1. Pharmaceuticals segment**
*Unit: Billions of yen, rounded to the nearest tenth*

	FY 2017 results		FY 2018 results		FY 2018 forecasts	
	Jan - Mar	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	%
Revenue	72.3	275.8	66.5	(5.8)	262.0	95%
Revenue from external customers	72.1	274.8	66.2	(5.9)	261.0	95%
Japan	50.1	197.8	45.4	(4.7)	181.0	91%
International	22.0	76.9	20.8	(1.2)	80.0	104%
International revenue ratio	30%	28%	31%	-	31%	-
Americas	5.1	15.0	4.2	(0.9)	20.8	138%
Europe	12.4	41.5	11.5	(0.9)	39.8	96%
Asia	4.3	19.6	4.9	0.6	18.8	96%
Others	0.2	0.8	0.2	0.0	0.6	82%
Inter-segment revenue	0.2	1.0	0.3	0.1	1.0	101%
Cost of sales	(22.5)	(79.1)	(19.8)	2.8	(70.0)	89%
Gross profit	49.7	196.7	46.7	(3.0)	192.0	98%
Selling, general and administrative expenses	(22.1)	(95.5)	(23.5)	(1.4)	(99.0)	104%
Research and development expenses	(11.3)	(46.1)	(10.2)	1.1	(46.5)	101%
Share of profit (loss) of investments accounted for using equity method	(1.3)	(4.5)	1.4	2.7	(3.5)	78%
Core operating profit	15.1	50.5	14.4	(0.7)	43.0	85%

\* Revenue is classified by region or country based on location of customer.

\* The figures represent amounts before elimination of inter-segment transactions.

**2. Bio-Chemicals segment**
*Unit: Billions of yen, rounded to the nearest tenth*

	FY 2017 results		FY 2018 results		FY 2018 forecasts	
	Jan - Mar	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	%
Revenue	20.0	81.1	19.0	(1.0)	76.0	94%
Revenue from external customers	19.2	78.6	18.5	(0.7)	74.0	94%
Japan	10.4	43.0	9.8	(0.6)	40.2	93%
International	8.8	35.6	8.7	(0.0)	33.8	95%
International revenue ratio	46%	45%	47%	-	46%	-
Americas	2.5	9.7	2.5	0.0	9.0	93%
Europe	3.4	14.4	3.6	0.2	15.4	107%
Asia	2.9	10.7	2.6	(0.3)	9.2	86%
Others	0.1	0.8	0.1	(0.0)	0.3	32%
Inter-segment revenue	0.8	2.5	0.5	(0.3)	2.0	79%
Cost of sales	(13.5)	(53.3)	(12.6)	0.9	(47.0)	88%
Gross profit	6.5	27.8	6.4	(0.0)	29.0	104%
Selling, general and administrative expenses	(4.2)	(17.6)	(4.5)	(0.3)	(18.0)	102%
Research and development expenses	(0.8)	(3.1)	(0.7)	0.0	(3.0)	98%
Core operating profit	1.5	7.2	1.2	(0.3)	8.0	111%

\* Revenue is classified by region or country based on location of customer.

\* The figures represent amounts before elimination of inter-segment transactions.

IV. Revenue from Main Products of Pharmaceuticals Segment (IFRS)

Unit: Billions of yen, rounded to the nearest tenth




Indication / Product name		FY 2017 results		FY 2018 results		FY 2018 forecasts	
		Jan - Mar	Jan - Dec	Jan - Mar	Change amount	Jan - Dec	%
Japan	Renal anemia treatment drug <b>Nesp</b>	12.5	56.3	12.0	(0.5)	52.4	93%
	Renal anemia treatment drug <b>Espo</b>	0.3	1.4	0.3	(0.0)	1.1	78%
	Secondary hyperparathyroidism <b>Regpara</b>	4.6	18.5	3.6	(1.0)	13.2	71%
	Secondary hyperparathyroidism <b>Rocaltrol</b>	0.9	4.1	0.9	(0.0)	3.5	87%
	Type-2 diabetes <b>Onglyza</b>	1.6	7.3	1.6	0.0	7.6	103%
	Cardiovascular (Hypertension & angina pectoris) <b>Coniel</b>	1.6	6.3	1.2	(0.3)	4.9	77%
	Agent for decreasing the incidence of febrile neutropenia <b>G-Lasta</b>	3.8	18.1	4.3	0.5	20.1	111%
	Neutropenia treatment drug <b>Gran</b>	0.7	3.3	0.5	(0.2)	2.7	83%
	Transdermal persistent pain <b>Fentos</b>	1.3	6.0	1.2	(0.1)	5.7	96%
	Anticancer <b>Poteligeo</b>	0.4	1.9	0.4	(0.0)	1.8	95%
	Chronic idiopathic thrombocytopenic purpura <b>Romiplate</b>	0.8	3.4	0.7	(0.0)	3.4	100%
	Antiallergenic <b>Allelock</b>	5.6	15.9	4.6	(1.0)	11.7	74%
	Antiallergic eyedrops <b>Patanol</b>	7.0	12.8	7.7	0.7	12.1	94%
	Ulcerative colitis <b>Asacol</b>	1.0	4.2	0.7	(0.3)	3.4	80%
	Psoriasis vulgaris <b>Dovobet</b>	1.2	5.3	1.2	(0.0)	6.2	117%
	Psoriasis <b>Lumicef</b>	0.1	1.0	0.4	0.3	2.7	281%
	Parkinson's disease <b>Nouriastr</b>	1.8	8.5	1.9	0.0	9.4	111%
	Antiepileptic <b>Depakene</b>	1.6	6.5	1.3	(0.3)	5.4	82%
	Gastrointestinal <b>Nauzelin</b>	0.6	2.5	0.5	(0.0)	2.1	85%
	<b>Technology out-licensing</b>	0.8	2.4	1.1	0.3	4.6	191%
International	Renal anemia treatment drug <b>Nesp</b>	1.4	5.7	1.5	0.1	5.8	103%
	Secondary hyperparathyroidism <b>Regpara</b>	0.5	2.2	0.7	0.1	2.8	123%
	Agent for decreasing the incidence of febrile neutropenia <b>Neulasta/Peglasta</b>	0.5	2.0	0.4	(0.0)	2.0	101%
	Neutropenia treatment drug <b>Gran</b>	1.0	5.2	1.4	0.3	4.4	86%
	Cancer pain <b>Abstral</b>	2.9	11.9	3.4	0.4	13.2	111%
	Cancer pain <b>PecFent</b>	1.1	4.1	1.0	(0.0)	5.2	128%
	Anticancer <b>Mitomycin-C</b>	0.8	3.4	0.6	(0.2)	2.0	57%
	Chemotherapy-induced nausea and vomiting drug <b>Sancuso</b>	0.6	3.0	0.6	(0.0)	2.8	92%
	Opioid-induced constipation (OIC) <b>Moventig</b>	0.2	0.8	0.3	0.1	2.4	299%
	Replacement therapy with testosterone for male hypogonadism <b>Tostran/Fortesta</b>	0.4	2.2	0.6	0.2	2.1	93%
	Relief of pain associated with chronic anal fissures <b>Rectogesic</b>	0.4	1.6	0.4	0.0	1.6	95%
	Osteoporosis drug <b>Adcal-D3</b>	0.8	3.6	0.9	0.1	3.3	93%
	<b>Technology out-licensing</b>	8.0	16.0	6.5	(1.5)	17.3	108%

\* Revenue is classified as Japan or International (other than Japan) based on customer location.










\* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment agreement, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use, etc. of technology.

V. R&D Pipeline













Filed • Approved

 antibody  protein  small molecule

As of March 31, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>KRN321</b> <b>Darbepoetin Alfa</b> <b>Injection</b>	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
		<b>KRN1493</b> <b>Cinacalcet</b> <b>Hydrochloride</b> <b>Oral</b>	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in BN	Licensed from Shire-NPS	
		© <b>KHK7580</b> <b>Evocalcet</b> <b>Oral</b>	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	Cutaneous T-cell Lymphoma	Filed in US Filed in EU Filed in JP	In-House	POTELLIGENT
		<b>Granisetron</b> <b>Patch</b>	5-HT <sub>3</sub> Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in MY	Licensed from Solasia Pharma	
Immunology /Allergy		© <b>KHK4563</b> <b>Benralizumab</b> <b>Injection</b>	Anti-IL-5 Receptor Humanized Antibody	Asthma	Approved in JP	In-House	POTELLIGENT Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
		<b>KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in TW Filed in TH Filed in SG Filed in MY	Kirin-Amgen	
Central Nervous System		<b>KW-6002</b> <b>Istradefylline</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other		© <b>KRN23</b> <b>Burosumab</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in pediatric patients	Approved in EU	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH)	Filed in US		




Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		© <b>RTA 402</b> <b>Baradoxolone Methyl</b> <b>Oral</b>	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata	
		© <b>KHK7580</b> <b>Evocalcet</b> <b>Oral</b>	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		© <b>KHK2375</b> <b>Entinostat</b> <b>Oral</b>	HDAC Inhibitor	Breast Cancer	Phase II in JP	Syndax	
		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT
Immunology /Allergy		© <b>KHK4083</b> <b>Injection</b>	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT Human Antibody-Producing Technology
		© <b>KHK4563</b> <b>Benralizumab</b> <b>Injection</b>	Anti-IL-5 Receptor Humanized Antibody	Chronic Obstructive Pulmonary Disease (COPD)	Phase III in JP	In-House	POTELLIGENT
				Eosinophilic Chronic Rhinosinusitis (E CRS)	Phase II in JP		Jointly Developed with AstraZeneca/MedImmune
		<b>KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Phase III in KR	Kirin-Amgen	
			Axial Spondyloarthritis (axSpA)	Phase III in JP, KR and TW			
		© <b>ASKP1240</b> <b>Bleselumab</b> <b>Injection</b>	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT
		© <b>KW-6356</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		© <b>KRN23</b> <b>Burosumab</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase III in US, CA, EU, AU, JP and KR		
				Tumor Induced Osteomalacia(TIO)/Epidermal Nevus Syndrome (ENS)	Phase II in US		
					Phase II in JP and KR		
		<b>AMG531</b> <b>Romiplostim</b> <b>Injection</b>	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II/III in JP and KR	Kirin-Amgen	
				Idiopathic (Immune) Thrombocytopenic Purpura	Phase III in CN		








 Updated since December 31, 2017 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

V. R&D Pipeline

Ph I

 antibody  protein  small molecule





As of March 31, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2455 Oral	IDO 1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I / II in US  Phase I in JP	In-House	POTELLIGENT  Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)  Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)
Immunology /Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase I in JP Phase I in JP	In-House	POTELLIGENT Human Antibody-Producing Technology
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	


 Updated since December 31, 2017 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

Updated since Dec. 31, 2017 (Area, Stage, Filed, Approved, etc.)

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		©KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		Granisetron Patch	5-HT <sub>3</sub> Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in MY	Licensed from Solasia Pharma	
Immunology /Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Approved in JP	In-House	POTELLIGENT Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in pediatric patients	Approved in EU	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US	In-House	POTELLIGENT  Combination with Durvalumab/Tremelimumab (Jointly Developed with AstraZeneca)  Combination with Docetaxel  Combination with PF-05082566 (Jointly Developed with Pfizer)



## &lt;Appendix&gt; Fujifilm Kyowa Kirin Biologics co. Ltd., Pipeline of Biosimilar

As of March 31, 2018

Code Name	Generic Name	Stage	Remarks
<b>FKB327</b>	Adalimumab (Fully Human Anti-TNF- $\alpha$ Monoclonal Antibody)	Filed in EU	Fujifilm Kyowa Kirin Biologics
<b>FKB238</b>	Bevacizumab (Humanized Anti-VEGF Monoclonal Antibody)	Phase III in US, Europe and others	Centus Biotherapeutics